BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11008905)

  • 1. Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families.
    Goldstein AM; Martinez M; Tucker MA; Demenais F
    Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):889-94. PubMed ID: 11008905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysplastic nevi in association with multiple primary melanoma.
    Titus-Ernstoff L; Duray PH; Ernstoff MS; Barnhill RL; Horn PL; Kirkwood JM
    Cancer Res; 1988 Feb; 48(4):1016-8. PubMed ID: 3338073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
    Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T
    J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene.
    Puig S; Ruiz A; Castel T; Volpini V; Malvehy J; Cardellach F; Lynch M; Mascaro JM; Estivill X
    Hum Genet; 1997 Dec; 101(3):359-64. PubMed ID: 9439668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p.
    Bale SJ; Dracopoli NC; Tucker MA; Clark WH; Fraser MC; Stanger BZ; Green P; Donis-Keller H; Housman DE; Greene MH
    N Engl J Med; 1989 May; 320(21):1367-72. PubMed ID: 2716782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population.
    Augustsson A; Stierner U; Rosdahl I; Suurküla M
    Acta Derm Venereol; 1991; 71(6):518-24. PubMed ID: 1685835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study.
    Halpern AC; Guerry D; Elder DE; Clark WH; Synnestvedt M; Norman S; Ayerle R
    Arch Dermatol; 1991 Jul; 127(7):995-9. PubMed ID: 2064418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [From gene to disease; from p16 to melanoma].
    Gruis NA; Bergman W
    Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Where have dysplastic nevi led us?
    Tucker MA
    Princess Takamatsu Symp; 1987; 18():251-9. PubMed ID: 3506542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma risk in individuals with clinically atypical nevi.
    Kang S; Barnhill RL; Mihm MC; Fitzpatrick TB; Sober AJ
    Arch Dermatol; 1994 Aug; 130(8):999-1001. PubMed ID: 8053717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetics of hereditary melanoma and nevi. 1998 update.
    Greene MH
    Cancer; 1999 Dec; 86(11 Suppl):2464-77. PubMed ID: 10630172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysplastic nevi and other risk markers for melanoma.
    Seykora J; Elder D
    Semin Oncol; 1996 Dec; 23(6):682-7. PubMed ID: 8970587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
    Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
    Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation analysis of the CDKN2A promoter in Australian melanoma families.
    Pollock PM; Stark MS; Palmer JM; Walters MK; Aitken JF; Martin NG; Hayward NK
    Genes Chromosomes Cancer; 2001 Sep; 32(1):89-94. PubMed ID: 11477665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
    Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
    J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.
    Goldstein AM; Liu L; Shennan MG; Hogg D; Tucker MA; Struewing JP
    Br J Cancer; 2001 Aug; 85(4):527-30. PubMed ID: 11506491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinico-genetic aspects of cutaneous melanoma. II. Interconnection and pathogenetic commonality with dysplastic nevus syndrome].
    Kharkevich GIu; Kazubskaia TP; Agapova RK; Musatov VK; Trubnikov VI; Demidov LV; Gar'kavtseva RF
    Genetika; 1995 Nov; 31(11):1562-5. PubMed ID: 8666223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for melanoma incidence in prospective follow-up. The importance of atypical (dysplastic) nevi.
    Schneider JS; Moore DH; Sagebiel RW
    Arch Dermatol; 1994 Aug; 130(8):1002-7. PubMed ID: 8053695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations.
    Bishop JA; Wachsmuth RC; Harland M; Bataille V; Pinney E; MacK P; Baglietto L; Cuzick J; Bishop DT
    J Invest Dermatol; 2000 Jan; 114(1):28-33. PubMed ID: 10620111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dysplastic nevus syndrome].
    Niebauer G; Kokoschka EM
    Wien Klin Wochenschr; 1986 Oct; 98(20):673-8. PubMed ID: 3788185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.